Clinical-Diagnostic Features of Duchenne Muscular Dystrophy in Children by Umida T. Omonova
INTERNATIONAL 
JOURNAL                
OF BIOMEDICINE
 International Journal of BioMedicine 3(4) (2013) 266-268
Clinical-Diagnostic Features of Duchenne Muscular Dystrophy in 
Children
Umida T. Omonova
Tashkent Medical Pediatric Institute, Tashkent, Uzbekistan
Abstract
Duchenne Muscular Dystrophy (DMD) is a severe, progressive disease that affects about 1 out of every 5,000 male infants; 
this is the most destructive of all muscular dystrophies, which worsens rapidly. In this study, we performed a clinical analysis 
of 37 children with DMD. They ranged in age from 3 to 15 years, mean age being 7.8±0.48 years. The mean age at onset 
was 4.3±0.36 years and ranged from birth to 8 years. The biochemical examination included the determination of the serum 
levels of the following enzymes, AST, ALT, CPK-MM, and LDH. A genealogical analysis was conducted among 240 first-degree 
relatives of children with DMD. Electroneuromyography examination included registration of the biopotentials of the hand and 
foot muscles, measurement of the muscle response (M-wave) and the late-evoked responses. The clinical-diagnostic features of 
DMD in children were characterized.
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Introduction
Among the different types of Muscular Dystrophies 
(MDs), Duchenne MD, Emery-Dreifuss MD and limb-girdle 
muscular dystrophy or Erb’s MD are diagnosed most often 
in children [1,2]. Duchenne Muscular Dystrophy (DMD) is 
a severe, progressive disease that affects about 1 out of every 
5,000 male infants[3,4]; this is the most destructive of all 
muscular dystrophies, which worsens rapidly [5].
DMD is caused by mutations in the dystrophin gene, 
which is located on the X chromosome. Due to the pattern of 
inheritance of the disease, only boys are affected, not girls. 
Therefore, the sons of females who are carriers of the disease 
(women with a defective gene but who express no symptoms 
themselves) each have a 50% chance of having the disease. 
The daughters each have a 50% chance of being carriers [6,7].
Despite the description of DMD being known almost 
a century ago, the pathogenesis, diagnosis and treatment of 
this disease are still unresolved [3,8]. DMD is a progressive 
disease, which eventually affects all the voluntary muscles 
and involves the heart and breathing muscles in the later 
stages. While the life expectancy is currently estimated 
to be around 25 years, this age span varies from patient to 
patient [6]. Recent advancements in medicine are extending 
the lifespan of those afflicted. Early planning of the supports 
required for later-life care has resulted in greater longevity in 
patients living with DMD.
The aim of this study was to investigate the clinical-
diagnostic features of DMD in children. 
Material and Methods
We performed a clinical analysis of 37 children with 
DMD. They ranged in age from 3 to 15 years, mean age being 
7.8±0.48 years. The mean age at onset was 4.3±0.36 years 
and ranged from birth to 8 years. Control group included 30 
healthy children of the same age range. 
The biochemical examination included the determination 
of the serum levels of the following enzymes, AST, ALT, 
CPK-MM, and LDH.
 A genealogical analysis was conducted among 240 first-
degree relatives (parents, siblings) of children with DMD. It 
included all the information related to the disease in three 
generations. Genealogical data were collected for both parent 
lines through the cross-examination of both parents, and 
sometimes the grandparents.
Electroneuromyography examination included registra-
tion of the biopotentials of the hand and foot muscles, 
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measurement of the muscle response (M-wave) and the late-
evoked responses. Statistical analysis was performed using 
the statistical software «Statistica».
Results and Discussion
The obstetric history showed that pregnancy with anemia 
occurred in 32.4% of cases, with the presence of toxemia in 
10.8% of cases. Also, 10.8% of the women suffered from acute 
respiratory infections during pregnancy. The exacerbation of 
chronic diseases during pregnancy was recorded in 2.7% of 
the mothers of the sick children. The average age of mothers at 
the time of the birth of the children with DMD was 26.0±0.85 
years.
The number of the family members with DMD was 
13.5%.  According  to  our  results,  DMD  was  identified  in 
siblings in 10.8% of the cases and in maternal uncles in 
2.7% of the cases. Analysis of the medical history detected 
the occurrence of consanguineous marriages in 13.5% of the 
cases. It also was noted that, in most cases, the children were 
born from 2nd or 3rd (2.2±0.19) pregnancy or 2nd or 3rd 
(2.15±0.17) childbirth. Two children were twins, of which one 
twin was healthy.
Childbirth was normal in 89.2% of the cases; a speedy 
delivery was noted in 5.4% of the cases, a prolonged dry period 
in 2.7% of the cases, and an operational delivery in 2.7% of 
the cases. The average birth weight was 3,130±107.3g. Cord 
entanglement was recorded in 5.4% of the children, while 8 
children were born in asphyxia.
The analysis of the development of psychomotor skills 
showed that the children, in most cases, revealed a delay in 
learning to hold up their heads and to sit up (after 9 months and 
more, in 51.3% of the cases). The psychomotor development 
was inconsistent with the age norm before the onset of the 
manifestations of DMD in 35.1% of the cases. 
Interestingly, MD was the preliminary diagnosis in 
78.4% of the cases. Only one of the 37 patients was under 
medical supervision, whereas the other patients were examined 
in the first visit. 
According to the literature, DMD symptoms usually 
appeared between 2 and 5 years of age. The muscles of the 
hips, pelvic area, thighs, shoulders, and calf muscles were 
affected first. According to our data, the first symptoms of the 
disease appeared at 4.6±0.35 years. 
The main clinical symptoms of DMD included, awkward 
manner of walking, stepping or running, toe walking;  frequent 
falls; difficulty with motor skills (running, hopping, jumping); 
increased lumbar lordosis leading to a shortening of the hip-
flexor muscles that affected the overall posture and manner of 
walking, stepping, or running; also, deformities of the chest 
and back (including scoliosis).
We noted symmetric pseudohypertrophy of the calf 
muscles. The pseudohypertrophy, was usually observed in 
children over 6 years. The pseudohypertrophy, however, 
tended to decrease with further progression of the disease. 
Tendo Achilles contracture occurred in 21.6% of the children. 
The typical skeletal deformities included lumbar 
lordosis (100%), kyphoscoliosis (94.6%), scoliosis (5.4%), 
keeled chest or funnel chest (32.4%), and high-arched feet 
(100%) (Fig. 1). With the progression of DMD, an equinovarus 
deformity and contractures of the large joints were observed 
to develop. Dental problems characterized by the expansion 
of the jaw and a widening of the gap between the teeth were 
observed in 67.6% of the children.  
Initially muscle atrophy was localized in the pelvic 
girdle muscles, with maximum expression in the proximal 
lower extremity muscles. With age, a tendency for the process 
to spread in an upward direction towards the muscles of the 
shoulder girdle, back and proximal upper extremity muscles 
was seen.
A neurological exam revealed the characteristic “duck 
walk” in 97.3% of the cases, while restriction of active 
movements  with  progressive  difficulty  in  walking  was 
observed in 72.9% of the cases. The decline and loss of the 
knee  reflexes  and  long-term  preservation  of  the  Achilles 
reflexes were noted. Reduced reflexes in the biceps and triceps 
were observed in older children. Total muscle hypotonia and 
reduced muscle strength, more pronounced in the legs, were 
observed in all the cases. The average foot muscle strength 
was 1.5±0.03; the average hand muscle strength was 2.2±0.07. 
Spastic syndrome was observed in two children and tremors 
in one patient.
Another distinctive feature of DMD is the combination 
of muscle atrophy with associated abnormalities in the 
cardiovascular and neuroendocrine systems as well as 
respiratory disorders. Cardiovascular disorders include 
lability of heart rate and blood pressure, deaf heart sounds, 
arrhythmias and the development of congestive heart failure. 
The ECG of patients with DMD was characterized by abnormal 
ventricular repolarization, bundle-branch block, and deep Q 
waves in the leads  II, III, aVF, V6, as well as tall T waves in 
lead V6. The advanced stage of DMD was often associated 
with hypertrophic cardiomyopathy (in 51.4% of the cases) and 
dilated cardiomyopathy (in 27% of the cases); however, mitral 
valve prolapse and left ventricular myxoma occurred in 21.6% 
of the cases. 
Neuro-endocrine disorders were found in 40.5% of the 
patients, including Cushing’s syndrome in 53.3% of the cases 
and adiposogenital dystrophy in 46.7% of the cases.
Psychomotor impairments and mental retardation were 
observed in 35.1% of the children.
Electroneuromyography was performed in all the 25 
children surveyed. In all the children, the M-response in 
the left and right tibialis anterior muscles was lower when 
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compared with the control group by almost in 3.5 times 
(p<0.001).  The rate of excitation propagation along a nerve 
was also significantly lower than in the control group on both 
sides (30.6±1.9 and 31.2±2.1 vs. 44.8±1.4 and 45.4±1.3; p<0.001).
Thus, in all of the children surveyed, a primary muscle 
lesion of the proximal lower extremity muscles with a tendency 
to progression and poor reinnervation was found. 
The high serum enzyme activity, particularly creatine 
phosphokinase  (CPK),  reflected  the  rate  of  myofibril 
degradation in the muscle fibers. Parallel with the elevated 
serum CPK levels, an increase in the serum concentration of 
the other cytolytic enzymes, such as aspartate aminotransferase 
(AST), alanine aminotransferase (ALT), and lactate 
dehydrogenase (LDH), was noted. Thus, the CPK levels had 
increased by 71 times; the ALT by 15.2 times, AST by 8.4 
times and LDH by 4.4 times compared with the control (n=20) 
(Fig. 2). 
The increased LDH level reflected the presence of hypoxia and 
impaired tissue respiration, which was clinically accompanied 
by the development of a feeling of muscle fatigue.
Conclusion
Thus, the diagnosis of DMD is a significant challenge 
that requires the use of special algorithms. Currently, the 
diagnosis of DMD is based on the data of clinical-genealogical 
anamnesis, clinical symptoms, as well as the results of 
electromyography, genetic tests, muscle biopsy and serum 
CPK-MM. Genetic counseling is advised if there is a family 
history of the disorder. DMD can be detected with about 95% 
accuracy by genetic studies performed during pregnancy.
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